Journal of Clinical Oncology
Articles in this Issue
Outpatient administration of cycle 1 of bispecific antibody therapy in hematologic malignancies: A real-world experience.
e19510 Background: Bispecific antibodies are increasingly used in hematologic malignancies but are commonly administered i...
Clinical and genomic predictors of outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
4560 Background: EVP is the recommended 1 st line (1L) therapy for pts with aUC an...
When does time become a burden? Evaluating the association between time spent on cancer care and patient distress.
11057 Background: While cancer care is time-intensive, the specific impact of various tasks on patient well-being is poorl...
Impact of the geographic redistribution of MMaT-3 policy on regional and socioeconomic disparities in hepatocellular carcinoma transplantation.
e23242 Background: The MMaT-3 (Median MELD at Transplant minus 3) policy was implemented in 2019 to reduce geographic vari...
Multidisciplinary onco–critical care management: Clinical impact.
e13568 Background: Advances in cancer diagnosis and treatment have increased survival, resulting in a growing number of pa...
Clinical impact of germline <i>BRCA1/2</i> variants on breast and ovarian cancer management in a resource-limited setting: Real-world data from Thailand.
e22654 Background: Identification of germline BRCA1/2 variants is critical for gui...
Real-world treatment and survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naive patients with chronic lymphocytic leukemia (CLL) in the United States.
7045 Background: Bruton tyrosine kinase (BTK) inhibitors are central to the management of CLL/SLL (hereafter referred to a...
Association between depth of IPRO-α response and overall survival (OS) in patients with advanced non–small cell lung cancer (aNSCLC) treated with first-line (1L) pembrolizumab monotherapy.
e20521 Background: Anticipating clinical benefit early in the treatment course remains a major challenge in oncology clini...
Significance of marrow complete remission (mCR) in higher-risk MDS: A meta-regressive assessment of surrogate endpoint validity.
e18580 Background: mCR is frequently used in trials evaluating therapies for higher-risk MDS (HR MDS) as an indicator of t...
Early palliative care and symptom-directed care utilization in pancreatic cancer: A national Epic Cosmos analysis.
e24089 Background: Pancreatic cancer is associated with high symptom burden and frequent acute care utilization. Although...
Ocular toxicity of belantamab mafodotin-based combination regimens in multiple myeloma: A systematic review of phase I-III clinical trials.
e19578 Background: Belantamab mafodotin (belamaf) is a B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate...
SARC045: A phase 2 trial of tebentafusp in HLA-A*02:01–positive patients with advanced clear cell sarcoma.
TPS11591 Background: Tebentafusp (Kimmtrak) is a first-in-class bispecific T-cell engager, specifically a T-cell receptor...
Biology-informed predictive modeling and resistance monitoring in trastuzumab deruxtecan–treated metastatic breast cancer.
1023 Background: The antibody-drug conjugate (ADC), trastuzumab deruxtecan (T-DXd), produces meaningful responses in metas...
Clinical validation of red blood cell DNA for early detection of advanced colorectal neoplasia: A single-center prospective observational case-control clinical trial.
3568 Background: Early detection of colorectal cancer (CRC) improves survival, but current screening is limited by poor co...
Patient-perceived caregiver burden after intense oncology treatment.
11104 Background: Although oncology caregiver burden is well-known (e.g. Alam, JCO...
An RNA sequencing approach for isoform detection of DPEP1 in colorectal cancer and in vitro characterization of a novel isoform.
e15734 Background: Microsatellite stable colorectal cancer (CRC) is historically poorly responsive to immunotherapy, due i...
Lung cancer burden in AYAs: Global and U.S. trends.
8603 Background: Lung cancer remains a leading cause of cancer-related mortality and is increasingly observed among adoles...
Clinical impact of genomic co-mutation profiles including TP53 in resected early-stage <i>EGFR</i> -mutated NSCLC: LC-SCRUM-Advantage.
8035 Background: Adjuvant osimertinib is the standard of care for resected stage IB–IIIA EGFR-mutated non-small cell lung...
STARS (NCT 07265661): Surgical timing after preoperative hypofractionated radiotherapy for patients with primary localized soft tissue sarcoma of the extremity and trunk—A randomized phase 2 clinical trial.
TPS11597 Background: Local management paradigm for localised soft tissue sarcoma of the extremities and trunk (ESTS) has r...
Clinical-genomic discordance and chemotherapy (CT) outcomes in early-stage HR+/HER2– invasive lobular carcinoma.
e12531 Background: Invasive lobular cancer (ILC) is biologically and clinically distinct from invasive ductal carcinoma (I...
Pemivibart for prevention of COVID-19: Subset analysis of CANOPY participants with solid tumor or hematologic malignancies.
2522 Background: Due to the chronic immunosuppression associated with both their condition and treatments, patients with s...
Temporal trends in metabolic syndrome–associated mortality among patients with upper gastrointestinal cancers, 1999–2020: A CDC WONDER analysis.
e16062 Background: Upper gastrointestinal (UGI) cancers remain a major cause of cancer mortality in the United States. Met...
Mechanical ventilation timing categories and inpatient outcomes in adult cancer hospitalizations: A 2018–2022 National Inpatient Sample analysis.
e23095 Background: Mechanical ventilation (MV) during cancer hospitalizations is commonly evaluated as a binary event, pot...
The efficacy of polatuzumab vedotin targeting CD79B in the treatment of non-Hodgkin lymphoma: A systematic review and meta-analysis.
e19085 Background: Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of lymphoid malignancies with a substantial...
Clinical outcomes of febrile neutropenia with colony stimulating factors: A multicenter retrospective analysis.
e24141 Background: Patients with solid and hematologic malignancies receiving cytotoxic chemotherapy are vulnerable to feb...